Results 121 to 130 of about 92,020 (286)

Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. [PDF]

, 2015
To elucidate the transcriptional 'landscape' that regulates human lymphoid commitment during postnatal life, we used RNA sequencing to assemble the long non-coding transcriptome across human bone marrow and thymic progenitor cells spanning the earliest ...
Casero, David, Crooks, Gay M, Ha, Vi Luan, Luong, Annie, Parekh, Chintan, Sandoval, Salemiz, Scholes, Jessica, Seet, Christopher S, Zhu, Yuhua   +8 more
core  

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy

Allergy, EarlyView.
Rapid clinical relief of allergy symptoms during 18 months of sublingual immunotherapy (SLIT) for house dust mite (HDM) is associated with increased serum IgE, IgG2, and IgG4 to Der p 1 and Der p 2. Der p 1 and Der p 2 specific Type 2 memory B cells are expanded at 4 months and 12 months of SLIT, with increased expression of CD29 and IgG4.
Lin Hsin, Simone Reinwald, Anouk von Borstel, Pei Mun Aui, Kirsten Deckert, P. Mark Hogarth, Laurent Mascarell, Mark Hew, Robyn E. O'Hehir, Menno C. van Zelm   +9 more
wiley   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Impaired bone marrow homing of cytokine-activated CD34⁺ cells in the NOD/SCID model [PDF]

, 2004
The reduced engraftment potential of hematopoietic stem/progenitor cells (HSPCs) after exposure to cytokines may be related to the impaired homing ability of actively cycling cells. We tested this hypothesis by quantifying the short-term horning of human
Ahmed, F, Blundell, MP, Fahey, A, Ings, SJ, Linch, DC, Pizzey, AR, Thrasher, AJ, Ye, HT, Yong, KL   +8 more
core  

CD38 as theranostic target in oncology

Journal of Translational Medicine
CD38 is a multifunctional transmembrane glycoprotein found in multiple tissues and overexpressed in many cancer cells, notably in hematological malignancies such as leukemia and multiple myeloma (MM). Therefore, targeting CD38 remains an attractive strategy for cancer treatment in hematological malignancies as well as in solid tumors.
Bocuzzi, Valentina, Bridoux, Jessica, PIROTTE, Michelle, Withofs, Nadia, Hustinx, Roland, D'Huyvetter, Matthias, Caers, Jo, Marcion, Guillaume   +7 more
openaire   +4 more sources

EXPRESSION OF MRNA CD16A, CD16B, ICAM1, CD38, FOXP3 IN TUMOR TISSUE OF PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA

Медицинская иммунология, 2019
Introduction. Diagnosis of kidney cancer presents significant difficulties, since symptoms of the disease may appear only at an advanced stage. Increasing attention is paid to the search for markers that allow for rapid and effective tumor diagnosis and ...
Z. V. Amoev, A. V. Alyasova, D. V. Novikov, O. O. Shkola, S. G. Selivanova, A. V. Kalugin, V. V. Novikov   +6 more
doaj  

CD38 promotes hematopoietic stem cell dormancy

PLOS Biology
A subpopulation of deeply quiescent, so-called dormant hematopoietic stem cells (dHSCs) resides at the top of the hematopoietic hierarchy and serves as a reserve pool for HSCs. The state of dormancy protects the HSC pool from exhaustion throughout life; however, excessive dormancy may prevent an efficient response to hematological stresses. Despite the
Liliia Ibneeva, Sumeet Pal Singh, Anupam Sinha, Sema Elif Eski, Rebekka Wehner, Luise Rupp, Iryna Kovtun, Juan Alberto Pérez-Valencia, Alexander Gerbaulet, Susanne Reinhardt, Manja Wobus, Malte von Bonin, Jaime Sancho, Frances Lund, Andreas Dahl, Marc Schmitz, Martin Bornhäuser, Triantafyllos Chavakis, Ben Wielockx, Tatyana Grinenko   +19 more
openaire   +4 more sources

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, EarlyView.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source